SINGAPORE - CooperVision has appointed Muru Annamalai as President, Asia-Pacific, effective June 1.
Annamalai brings over 20 years of global leadership experience in pharmaceutical and healthcare sectors. Previously, he held senior roles at AbbVie and Abbott, and most recently served as Vice President at TCA Venture Group.
"Muru is exactly the kind of leader who can accelerate CooperVision’s growth, deepen customer partnerships, and expand access to our portfolio across Asia-Pacific," said Debbie Olive, Chief Commercial Officer.
Annamalai holds a bachelor’s degree in mathematics from University Malaya and an MBA from Heriot-Watt University in the UK. He is originally from Malaysia.
CooperVision is a division of CooperCompanies (NASDAQ:COO), a medical device company with two units: CooperVision and CooperSurgical. Headquartered in San Ramon, California, the company employs over 15,000 people and sells products in more than 130 countries. With a market cap of $11.91 billion and revenue of $4.15 billion over the last twelve months, the stock trades near its 52-week low at $61.04. According to Bond.az analysis, the company appears undervalued at current levels. Investors can access a comprehensive Pro Research Report on CooperCompanies, one of 1,400+ US equities covered with detailed analysis and actionable intelligence.
In other recent news, Cooper Companies reported Q1 fiscal 2026 results that met revenue expectations and exceeded EPS consensus. Needham raised its price target to $101 with a Buy rating, and the company raised its full-year fiscal 2026 EPS guidance. Barclays also adjusted its price target to $103, citing growth in Vision and Surgical segments, despite declines in older hydrogel products in Japan.
Additionally, Cooper Companies' Board appointed Paul Keel as an independent director, effective July 1, 2026. Keel will serve on the Audit Committee. Wolfe Research identified Cooper Companies as a new investment idea, highlighting its position in the global contact lens market amid ongoing activist involvement.
At the 2026 Annual Meeting, all nominated directors were elected to serve until the 2027 Annual Meeting. Elected directors include Colleen E. Jay, Barbara A. Carbone, and others.
This article was generated with AI support and reviewed by an editor. For more information, see our T&C.
